Search ARM

Considerations for Cell & Gene Therapy Companies Contemplating Foreign Direct Investment in Japan

The Alliance for Regenerative Medicine (ARM) is committed to serving our membership by enabling the development of and access to cell and gene therapies. Through ARM’s Managed Growth Working Group, an initiative aimed at identifying how ARM can refine and expand its work to better serve our member organization, ARM is crafting a geographic expansion strategy that includes the Asia Pacific region. To support this strategy, ARM partnered with JLL to lay out the key considerations for companies contemplating foreign direct investment in Japan, including supply chain, labor, and real estate. This white paper is an essential resource for investors, service providers, and business leaders!

Download Report